Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/33593161http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/33593161http://www.w3.org/2000/01/rdf-schema#comment"

Introduction

IL-36 is a new member of the IL-1 family with pro-inflammatory properties. Serum levels of IL-36 are elevated in patients with Systemic Lupus Erythematosus (SLE). However, no data is available on urinary levels of IL-36 in Lupus Nephritis (LN). In psoriasis expression of IL-36 is site specific and expressed in skin. Hence, we studied urinary levels of IL-36 cytokines in SLE patients.

Methods

A total of 196 patients with SLE [97 active LN patients (ALN), 42 inactive LN (ILN) and 57 active lupus patients with no renal involvement (ANR)] and 25 healthy subjects were recruited for the study after obtaining informed consent. Urinary and plasma IL-36α, IL-36γ and IL-36Ra levels were measured by ELISA.

Results

Out of 196 patients 178 were females. Urinary IL-36γ levels in SLE patients [0(14.3) pg/ml] were significantly higher than healthy controls [0(0) pg/ml, (P < 0.01)]. Patients with ALN [0(40.6) pg/ml] had significantly higher IL-36γ when compared to ANR [0(0) pg/ml] as well as ILN [0(0) pg/ml]. Urinary IL-36γ levels in ALN patients had a fair correlation with renal SLEDAI (r = 0.26, P = 0.004).The levels reduced significantly post 3 months in patients with ALN. No inverse relationship was noted between IL-36Ra and IL-36α/IL36γ levels.

Conclusion

Urinary IL-36γ is produced locally in kidney, correlates with renal disease activity and reduces upon treatment, suggesting that it may have a role in pathogenesis of LN."xsd:string
http://purl.uniprot.org/citations/33593161http://purl.org/dc/terms/identifier"doi:10.1177/0961203321995246"xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/author"Singh P."xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/author"Aggarwal A."xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/author"Majumder S."xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/author"Chatterjee R."xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/author"Pattnaik S.S."xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/date"2021"xsd:gYear
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/name"Lupus"xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/pages"921-925"xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/title"Elevated urinary IL-36gamma in patients with active lupus nephritis and response to treatment."xsd:string
http://purl.uniprot.org/citations/33593161http://purl.uniprot.org/core/volume"30"xsd:string
http://purl.uniprot.org/citations/33593161http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/33593161
http://purl.uniprot.org/citations/33593161http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/33593161
http://purl.uniprot.org/uniprot/#_Q9NZH8-mappedCitation-33593161http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/33593161
http://purl.uniprot.org/uniprot/Q9NZH8http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/33593161